FDA's Million-Dollar Blunder: Ignoring Fentanyl and Meth Crisis for Adderall Case in Minneapolis
Minneapolis, MN – In a shocking misuse of federal power, FDA Special Agent Heidi Whereatt has spent years and is on track to waste over a million taxpayer dollars on an Adderall case, while Minneapolis sinks under a deadly wave of methamphetamine and fentanyl. The investigation reveals the FDA's monumental failure to address the Adderall shortage, pushing desperate users towards lethal street drugs.
Whereatt, originally hired as secret service, fixated on a local Adderall seller, ignoring the catastrophic rise in meth and fentanyl use. The FDA's mismanagement since 2022 has left patients turning to meth, which can cause severe addiction, psychosis, and heart failure, while fentanyl, 50 times more potent than heroin, leads to fatal overdoses. In 2021, over 35,000 Americans died from fentanyl mixed with stimulants, a 32% spike in deaths.
"My brother died from fentanyl, and the FDA is chasing Adderall? Unbelievable,” one user posted.
Minneapolis has become a battleground in the fentanyl crisis, with residents on X expressing outrage under #FentanylCrisis. Critics argue this reflects a disastrous misplacement of federal priorities, with Dr. Sarah Kline stating, "Meth destroys lives in ways Adderall never could."
As the city fights for survival, citizens demand answers: Why did Whereatt and the FDA OCI focus on Adderall when meth and fentanyl are the real killers? Though the case is unconventional, the prosecutor insists on moving forward, arguing that he doesn’t want the extensive effort invested to be squandered.
FDA's staggering failure to address the Adderall shortage, pushing desperate users to destructive meth, fueling the city's drug crisis.
TOP STORIES
